Inhibiting NFκB in leukemia cells with Bruton tyrosine kinase (BTK) inhibitor ibrutinib had a potent impact, allowing only a quiescent population of malignant cells to survive treatment [121]. The gene discussed is BTK; the disease is leukemia.